{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:38:06Z","timestamp":1783463886933,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T00:00:00Z","timestamp":1410998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s13023-014-0147-z","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T15:23:03Z","timestamp":1410967383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Rare diseases and orphan drugs: Latvian story"],"prefix":"10.1186","volume":"9","author":[{"given":"Konstantins","family":"Logviss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dainis","family":"Krievins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santa","family":"Purvina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,18]]},"reference":[{"key":"147_CR1","unstructured":"Regulation (EC) No. 141\/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Offic J Europ Communities. 2000, L18: 1-5. Available from http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF. Accessed 18.04.2014, [ http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF ]"},{"key":"147_CR2","unstructured":"Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Offic J Europ Communities. 2009, C151: 7-10. Available from http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF. Accessed 29.01.2014, [ http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF ]"},{"key":"147_CR3","unstructured":"Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the regions on Rare Diseases: Europe\u2019s challenges. 2008, Commission of the European Communities, Brussels"},{"key":"147_CR4","unstructured":"List of rare disease designations. European Medicines Agency, Available from http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/orphan_seasea.jsp&mid=WC0b01ac058001d12b. Accessed 18.04.2014, [ http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/orphan_seasea.jsp&mid=WC0b01ac058001d12b ]"},{"key":"147_CR5","unstructured":"European Community Register of designated orphan medicinal products. European Commission. Available from http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/alforphreg.htm. Accessed 18.04.2014, [ http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/alforphreg.htm ]"},{"key":"147_CR6","volume-title":"2013 Report on the State of the Art of Rare Disease Activities in Europe","author":"S Aym\u00e9","year":"2013","unstructured":"Aym\u00e9 S, Rodwell C: 2013 Report on the State of the Art of Rare Disease Activities in Europe. 2013, Available from http:\/\/www.eucerd.eu\/upload\/file\/Reports\/2013ReportStateofArtRDActivitiesLV.pdf. Accessed 29.01.2014, [ http:\/\/www.eucerd.eu\/upload\/file\/Reports\/2013ReportStateofArtRDActivitiesLV.pdf ]"},{"key":"147_CR7","unstructured":"National Plan for Rare Diseases for the period from 2013 to 2015. Available from http:\/\/www.vm.gov.lv\/images\/userfiles\/reto_slimibu_plans_13_15.pdf. Accessed 29.01.2014, [ http:\/\/www.vm.gov.lv\/images\/userfiles\/reto_slimibu_plans_13_15.pdf ]"},{"key":"147_CR8","volume-title":"2014 Report on the State of the Art of Rare Disease Activities in Europe","author":"C Rodwell","year":"2014","unstructured":"Rodwell C, Aym\u00e9 S: 2014 Report on the State of the Art of Rare Disease Activities in Europe. 2014, Available from http:\/\/www.eucerd.eu\/upload\/file\/Reports\/2014ReportStateofArtRDActivitiesV.pdf. Accessed 08.08.2014, [ http:\/\/www.eucerd.eu\/upload\/file\/Reports\/2014ReportStateofArtRDActivitiesV.pdf ]"},{"key":"147_CR9","unstructured":"Register of patients suffering from certain diseases. Available from https:\/\/www.visr.eps.gov.lv\/visr\/default.aspx?action=2&rid=138. Accessed 29.01.2014, [ https:\/\/www.visr.eps.gov.lv\/visr\/default.aspx?action=2&rid=138 ]"},{"key":"147_CR10","unstructured":"Statistical yearbook of health care in Latvia. 2012, Available from http:\/\/www.spkc.gov.lv\/veselibas-aprupes-statistika\/. Accessed 18.04.2014, [ http:\/\/www.spkc.gov.lv\/veselibas-aprupes-statistika\/ ]"},{"key":"147_CR11","unstructured":"Latvian Biomedical Research and Study Center. Available from http:\/\/biomed.lu.lv\/gene\/KASirgenomadatubaze.htm. Accessed 29.01.2014, [ http:\/\/biomed.lu.lv\/gene\/KASirgenomadatubaze.htm ]"},{"key":"147_CR12","unstructured":"P3G Catalogue. Available from http:\/\/www.p3gobservatory.org\/catalogue.htm;jsessionid=ACE6E593F10B80573D64E965FA2DB3D8?measureId=18. Accessed 29.01.2014, [ http:\/\/www.p3gobservatory.org\/catalogue.htm;jsessionid=ACE6E593F10B80573D64E965FA2DB3D8?measureId=18 ]"},{"key":"147_CR13","unstructured":"Oncological Diseases Control Program for period of 2009-2015. Regulation No. 48 of the Cabinet of Ministers of the Republic of Latvia. Adopted on the 29 January 2009. Available from http:\/\/www.epaac.eu\/from_heidi_wiki\/Latvia_-_Oncolgical_Diseases_Control_Programme_2009-2015,_Latvi.pdf. Accessed 16.04.2014, [ http:\/\/www.epaac.eu\/from_heidi_wiki\/Latvia_-_Oncolgical_Diseases_Control_Programme_2009-2015,_Latvi.pdf ]"},{"key":"147_CR14","unstructured":"Statistics on the number of patients by region, types of localization, gender and age groups from 2009 to 2012. Center for Disease Prevention and Control, Updated 22.07.2013. Available from http:\/\/www.spkc.gov.lv\/veselibas-aprupes-statistika\/. Accessed 17.04.2014, [ http:\/\/www.spkc.gov.lv\/veselibas-aprupes-statistika\/ ]"},{"issue":"17","key":"147_CR15","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","volume":"47","author":"G Gatta","year":"2011","unstructured":"Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R: Rare cancers are not so rare: The rare cancer burden in Europe. Eur J Cancer. 2011, 47 (17): 2493-2511. 10.1016\/j.ejca.2011.08.008.","journal-title":"Eur J Cancer"},{"key":"147_CR16","unstructured":"Cardiovascular Health Improvement Action Plan for period of 2013-2015. Available from http:\/\/www.vm.gov.lv\/images\/userfiles\/sirds_plans_07_2013.pdf. Accessed 08.08.2014, [ http:\/\/www.vm.gov.lv\/images\/userfiles\/sirds_plans_07_2013.pdf ]"},{"key":"147_CR17","unstructured":"Available from http:\/\/www.bkus.lv\/page\/?main_page_id=&page_type=&second_page_id=&news_id=685. Accessed 29.01.2014, [ http:\/\/www.bkus.lv\/page\/?main_page_id=&page_type=&second_page_id=&news_id=685 ]"},{"key":"147_CR18","volume-title":"2012 Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases","author":"S Aym\u00e9","year":"2012","unstructured":"Aym\u00e9 S, Rodwell C: 2012 Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases. 2012, Available from http:\/\/www.eucerd.eu\/?post_type=document&p=1501. Accessed 29.01.2014, [ http:\/\/www.eucerd.eu\/?post_type=document&p=1501 ]"},{"key":"147_CR19","unstructured":"Rare Disease Registries in Europe. 2014, Available from http:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Registries.pdfAccessed 29.01.2014, [ http:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Registries.pdf ]"},{"key":"147_CR20","unstructured":"Statistics of Center for Disease Prevention and Control. 2012, Available from http:\/\/www.spkc.gov.lv\/veselibas-aprupes-statistika\/. Accessed 18.04.2014, [ http:\/\/www.spkc.gov.lv\/veselibas-aprupes-statistika\/ ]"},{"key":"147_CR21","unstructured":"Inventory of Community and Member States\u2019 incentive measures to aid the research, marketing, development and availability of orphan medicinal products. 2005 revision: 16-17. Available from http:\/\/ec.europa.eu\/health\/files\/orphanmp\/doc\/inventory_2006_08_en.pdf. Accessed 29.01.2014, [ http:\/\/ec.europa.eu\/health\/files\/orphanmp\/doc\/inventory_2006_08_en.pdf ]"},{"key":"147_CR22","unstructured":"Cito! Newsletter of State Agency of Medicines of Latvia 2012. 1 (48): 7-9. Available from http:\/\/www.zva.gov.lv\/doc_upl\/cito-nr48-web.pdf. Accessed 20.04.2014, [ http:\/\/www.zva.gov.lv\/doc_upl\/cito-nr48-web.pdf ]"},{"key":"147_CR23","unstructured":"Order of reimbursement of medicines and medical devices for outpatient treatment. In 2006, Riga, Version of 01.01.2014. Available from http:\/\/likumi.lv\/doc.php?id=147522. Accessed 29.01.2014, [ http:\/\/likumi.lv\/doc.php?id=147522 ]"},{"key":"147_CR24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.healthpol.2010.05.017","volume":"97","author":"A Denis","year":"2010","unstructured":"Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S: A comparative study of European rare disease and orphan drug markets. Health Policy. 2010, 97: 173-179. 10.1016\/j.healthpol.2010.05.017.","journal-title":"Health Policy"},{"key":"147_CR25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.healthpol.2012.08.013","volume":"108","author":"G Iskrov","year":"2012","unstructured":"Iskrov G, Miteva-Katrandzhieva T, Stefanov R: Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria. Health Policy. 2012, 108: 10-18. 10.1016\/j.healthpol.2012.08.013.","journal-title":"Health Policy"},{"issue":"5","key":"147_CR26","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.5504\/BBEQ.2012.0085","volume":"26","author":"N Pavlovi\u0107","year":"2012","unstructured":"Pavlovi\u0107 N, Stanimirov B, Stojan\u010devi\u0107 M, Paut-Kusturica M, Stoimenova A, Golo\u010dorbin-Kon S, Mikov M: An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden. Biotechnol Biotec Eq. 2012, 26 (5): 3236-3241. 10.5504\/BBEQ.2012.0085.","journal-title":"Biotechnol Biotec Eq"},{"key":"147_CR27","unstructured":"Bignami F: Eurordis survey on orphan drugs availability in Europe. In 2007, Barcelona, Available from http:\/\/www.eurordis.org\/IMG\/pdf\/2007ODsurvey-eurordis.pdf. Accessed 02.05.2014, [ http:\/\/www.eurordis.org\/IMG\/pdf\/2007ODsurvey-eurordis.pdf ]"},{"key":"147_CR28","volume-title":"Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & Eurordis","author":"Y Le Cam","year":"2010","unstructured":"Le Cam Y: Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & Eurordis. In 2010, Paris, Available from http:\/\/img.eurordis.org\/newsletter\/pdf\/mar-2011\/ERTC_13122010_YLeCam_Final.pdf. Accessed 02.05.2014, [ http:\/\/img.eurordis.org\/newsletter\/pdf\/mar-2011\/ERTC_13122010_YLeCam_Final.pdf ]"},{"key":"147_CR29","volume-title":"Study on orphan drugs: Phase I: overview of the conditions for marketing orphan drugs in Europe","author":"A de Varax","year":"2004","unstructured":"de Varax A, Letellier M, B\u00f6rtlein G: Study on orphan drugs: Phase I: overview of the conditions for marketing orphan drugs in Europe. In 2004, Alcimed, Paris, Available from http:\/\/ec.europa.eu\/health\/files\/orphanmp\/doc\/pricestudy\/final_final_report_part_1_web_en.pdf. Accessed 02.05.2014, [ http:\/\/ec.europa.eu\/health\/files\/orphanmp\/doc\/pricestudy\/final_final_report_part_1_web_en.pdf ]"},{"issue":"1","key":"147_CR30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/erp.11.95","volume":"12","author":"M Michel","year":"2012","unstructured":"Michel M, Toumi M: Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012, 12 (1): 23-29. 10.1586\/erp.11.95.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"8","key":"147_CR31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/medicina44080074","volume":"44","author":"I Spokiene","year":"2008","unstructured":"Spokiene I: Legal assessment of current situation on orphan patients in Lithuania. Medicina (Kaunas). 2008, 44 (8): 571-576.","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"147_CR32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0266462307051550","volume":"23","author":"MF Drummond","year":"2007","unstructured":"Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J: Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007, 23 (1): 36-42. 10.1017\/S0266462307051550.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"147_CR33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/11590170-000000000-00000","volume":"9","author":"E Picavet","year":"2011","unstructured":"Picavet E, Dooms M, Cassiman D, Simoens S: Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy. 2011, 9 (4): 275-279. 10.2165\/11590170-000000000-00000.","journal-title":"Appl Health Econ Health Policy"},{"key":"147_CR34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-6-42","volume":"6","author":"S Simoens","year":"2011","unstructured":"Simoens S: Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011, 6: 42-10.1186\/1750-1172-6-42.","journal-title":"Orphanet J Rare Dis"},{"key":"147_CR35","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.socscimed.2008.01.012","volume":"66","author":"W Boon","year":"2008","unstructured":"Boon W, Moors E: Exploring emerging technologies using metaphors\u2013a study of orphan drugs and pharmacogenomics. Soc Sci Med. 2008, 66: 1915-1927. 10.1016\/j.socscimed.2008.01.012.","journal-title":"Soc Sci Med"},{"key":"147_CR36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1750-1172-6-62","volume":"6","author":"C Schey","year":"2011","unstructured":"Schey C, Milanova T, Hutchings A: Estimating the budget impact of orphan medicines in Europe: 2010\u20132020. Orphanet J Rare Dis. 2011, 6: 62-10.1186\/1750-1172-6-62.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"147_CR37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3111\/13696998.2010.491427","volume":"13","author":"A Denis","year":"2010","unstructured":"Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S: Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010, 13 (2): 295-301. 10.3111\/13696998.2010.491427.","journal-title":"J Med Econ"},{"issue":"5","key":"147_CR38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/11531880-000000000-00000","volume":"8","author":"J Orofino","year":"2010","unstructured":"Orofino J, Soto J, Casado MA, Oyag\u00fcez I: Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy. 2010, 8 (5): 301-315. 10.2165\/11531880-000000000-00000.","journal-title":"Appl Health Econ Health Policy"},{"key":"147_CR39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1172-9-22","volume":"9","author":"A Hutchings","year":"2014","unstructured":"Hutchings A, Schey C, Dutton R, Achana F, Antonov K: Estimating the budget impact of orphan drugs in Sweden and France 2013\u20132020. Orphanet J Rare Dis. 2014, 9: 22-10.1186\/1750-1172-9-22.","journal-title":"Orphanet J Rare Dis"},{"key":"147_CR40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1365-2710.2012.01364.x","volume":"37","author":"E Picavet","year":"2012","unstructured":"Picavet E, Annemans L, Cleemput I, Cassiman D, Simoens S: Market uptake of orphan drugs \u2013 a European analysis. J Clin Pharm Ther. 2012, 37: 664-667. 10.1111\/j.1365-2710.2012.01364.x.","journal-title":"J Clin Pharm Ther"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-014-0147-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-014-0147-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-014-0147-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T03:25:17Z","timestamp":1565839517000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-014-0147-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,18]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["147"],"URL":"https:\/\/doi.org\/10.1186\/s13023-014-0147-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,18]]},"article-number":"147"}}